The cost effectiveness of radon mitigation in existing German dwellings - A decision theoretic analysis

Journal of Environmental Management

Volumn 91, Issue 11, 2010, Pages 2263-2274

  Haucke, Florian ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cost effectiveness analysis; Legal regulations; Lung cancer; Natural radiation; QALY; Radon; Relative risk

Indexed keywords

BIOLOGICAL ORGANS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS; DISEASES; HOUSING; INTELLIGENT SYSTEMS; LAWS AND LEGISLATION; MONTE CARLO METHODS; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

COST EFFECTIVE; COST EFFECTIVENESS ANALYSIS; DECISION-THEORETIC; INTERVENTION STRATEGY; LEGAL REGULATION; LUNG CANCER; NATURAL RADIATION; PROBABILISTIC SENSITIVITY ANALYSIS; QUALITY ADJUSTED LIFE YEAR; RELATIVE RISKS;

RADON;

RADON;

CANCER; COST-BENEFIT ANALYSIS; DECISION ANALYSIS; HEALTH RISK; MITIGATION; MONTE CARLO ANALYSIS; RADIATION EXPOSURE; RADIOACTIVITY; RADON; REGULATORY FRAMEWORK; RISK FACTOR; SENSITIVITY ANALYSIS; SOCIAL HOUSING;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; ENVIRONMENTAL RADIOACTIVITY; GERMANY; LEGAL ASPECT; MONTE CARLO METHOD; QUALITY ADJUSTED LIFE YEAR; RESPONSIBILITY; SENSITIVITY AND SPECIFICITY; SOCIETY;

GERMANY;

EID: 77955511992     PISSN: 03014797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jenvman.2010.06.015     Document Type: Article

References (82)

1. Akerblom G. Radon Legislation and National Guidelines 1999, Swedish Radiation Protection Institute, SSI Report, pp. 99-18. 0282-4434.
2. Alavanja M.C., Lubin J.H., Mahaffey J.A., Brownson R.C. Residential radon exposure and risk of lung cancer in Missouri. Am. J. Public Health 1999, 89:1042-1048.
3. APUG Vermeidung und Verminderung der Radonbelastung von Innenräumen 2005, Action Programme Environment and Health, Berlin, (accessed 29.04.10.). http://www.apug.de/uug/strahlung/radon-wohnungen.htm.
4. Azimi N.A., Welch H. The effectiveness of cost-effectiveness analysis in containing costs. J. Gen. Intern. Med. 1998, 13:664-669.
5. Bastian H., Bender R., Ernst A.S., Kaiser T., Kirchner H., Kolominsky-Rabas P., Lange S., Sawicki P.T., W M. Entwurf einer Methodik für die Bewertung von Verhältnissen zwischen Nutzen und Kosten im System der deutschen gesetzlichen Krankenversicherung. Technischer Anhang Modellierung 2008, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, Köln.
6. BfS Radonhandbuch Deutschland. B. f. Strahlenschutz 2005, Verlag für Neue Wissenschaft GmbH, Bremerhaven.
7. Birk T., Mundt K.A., Dell L.D., Luippold R.S., Miksche L., Steinmann-Steiner-Haldenstaett W., Mundt D.J. Lung cancer mortality in the German chromate industry, 1958 to 1998. J. Occup. Environ. Med. 2006, 48:426-433.
8. Bradley E.J. Responses to radon remediation advice. Proceedings to the 9th Int. Congress 1996, 798-800. International Radiation Protection Association.
9. Briggs A. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000, 15:479-500.
10. Briggs A., Claxton K., Sculpher M. Decision modelling for health economic evaluation. New York 2006, Oxford University Press. A. Gray, A. Briggs (Eds.).
11. Brooks R.G., Jendteg S., Lindgren B., et al. EuroQol: health related quality of life measurement: results of the Swedish questionnaire exercise. Health Policy 1991, 18:37-48.
12. Brüske-Hohlfeld I., Kreienbock L., Wichmann H.-E. Inhalation natürlicher Strahlung. Lungenkrebs durch Radon. Mensch+Umwelt Spezial: Strahlung 2006, 18:37-45.
13. Brüske-Hohlfeld I., Rosario A.S., Wölke G., Heinrich J., Kreuzer M., Kreienbrock L., Wichmann H.E. Lung cancer risk among former uranium miners of the WISMUT Company in Germany. Health Phys. 2006, 90.
14. Claxton K., Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 1996, 5:513-524.
15. Clegg A., Scott D.A., Sidhu M., Hewitson P., Waugh N. Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer: a systematic review. Thorax 2002, 57:20-28.
16. Colgan P.A., Gutiirrez J. Justification and optimisation in the choice of Reference Levels for radon in existing Spanish dwellings. J. Radiol. Prot. 1995, 15:289-301.
17. Coskeran T., Denman A., Phillips P.S., Gillmore G.K. A critical comparison of domestic radon remediation programmes in five areas of England. J. Environ. Radioact. 2002, 62:129.
18. Coskeran T., Denman A., Phillips P., Gillmore G., Tornberg R. A new methodology for cost-effectiveness studies of domestic radon remediation programmes: quality-adjusted life-years gained within Primary Care Trusts in Central England. Sci. Total Environ. 2006, 366:32-46.
19. Coskeran T., Denman A., Phillips P., Tornberg R. A cost-effectiveness analysis of radon protection methods in domestic properties: a comparative case study in Brixworth, Northamptonshire, UK. J. Environ. Radioact. 2006, 91:73-89.
20. Coskeran T., Denman A., Phillips P., Tornberg R. A critical evaluation of the cost-effectiveness of radon protection methods in new homes in a radon Affected Area of England. Environ. Int. 2009, 35:943-951.
21. Darby S., Whitley E., Silcocks P., Thakrar B., Green M., Lomas P., Miles J., Reeves G., Fearn T., Doll R. Risk of lung cancer associated with residential radon exposure in south-west England: a case-control study. Br. J. Cancer 1998, 78:394-408.
22. Darby S., Hill D., Auvinen A., Barros-Dios J.M., Baysson H., Bochicchio F., Deo H., Falk R., Forastiere F., Hakama M., Heid I., Kreienbrock L., Kreuzer M., Lagarde F., Mäkeläinen I., Muirhead C., Oberaigner W., Pershagen G., Ruano-Ravina A., Ruosteenoja E., Schaffrath-Rosario A., Tirmarche M., Tomábek L., Whitley E., Wichmann H.-E., Doll R. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. Br. Med. J. 2004, 330:223-228.
23. Denman A., Groves-Kirkby C., Coskeran T., Parkinson S., Phillips P., Tornberg R. Evaluating the health benefits and cost-effectiveness of the radon remediation programme in domestic properties in Northamptonshire. UK Health Policy 2005, 73:139-150.
24. Department of Health Policy Appraisal and Health: a Guide for Policy Makers 1995, HMSO, London.
25. Desvousges H.W., Cox J.A. Radon Focus Groups: A Summary 1986, Research Triangle Centre, Research Triangle Park: NC.
26. Doyle J.K., McClelland G.H., Schulze W.D., Locke P.A., Elliott S.R., Russell G.W., Moyad A. Economics and Psychology Policy Research for Environmental Management. An Evaluation of Strategies for Promoting Effective Radon Mitigation 1990, Environmental Protection Agency, Washington, DC.
27. Doyle J.K., McClelland G.H., Schulze W.D., Elliott S.R., Russell G.W. Protective responses to household risk: a case study of radon mitigation. Risk Anal. 1991, 11:121-134.
28. EPA Consumer's Guide to Radon Reduction. How to Fix Your Home 2006, Environmental Protection Agency, EPA 402-K-06-094.
29. Ettenhuber E., Jung T., Kreuzer M., Kirchner G., Lehmann R., Meyer W. Das Radonschutzgesetz - Ein neuer deutscher Weltrekord?. StrahlenschutzPraxis 2005, 4:65-67.
30. Ettenhuber, E., Kreuzer, M., Kirchner, G., Lehmann, R., Meyer, W., Jung, T., 2005b. Principles for the control of exposures to radon in dwellings-conception for a national radon programme in Germany. Proceedings to the 7th International Symposium of the Society for Radiological Protection, Cardiff, pp. 420-425.
31. Ford E.S., Eheman C.R. Radon retesting and mitigation behavior among the U.S. population. Health Phys. 1997, 72:611-614.
32. Ford E.S., Kelly A.E., Teutsch S.M., Thacker S.B., Garbe P.L. Radon and lung cancer: a cost-effectiveness analysis. Am. J. Public Health 1999, 89:351-357.
33. Gray A., Read S., McGale P., Darby S. Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them. Br. Med. J. 2009, 338:a3110.
34. Groves-Kirkby C.J., Denman A.R., Phillips P.S., Tornberg R., Woolridge A.C., Crockett R.G.M. Domestic radon remediation of U.K. dwellings by sub-slab depressurisation: evidence for a baseline contribution from constructional materials. Environ. Int. 2008, 34:428-436.
35. Guhr, A., 2005. Die Strahlenexposition der Bevölkerung beim Aufenthalt in Gebäuden Messtechnische Erfassung der Radonkonzentration. 1. Tagung Radonsicheres Bauen, Berlin.
36. Guhr A., Leißring B. Gesundheitsrisiko infolge natürlicher Radioaktivität in Wohn- und Aufenthaltsräumen. Umwelt-Medizin-Gesellschaft 2005, 18:126-129.
37. Hagemeyer O., Otten H., Kraus T. Asbestos consumption, asbestos exposure and asbestos-related occupational diseases in Germany. Int. Arch. Occup. Environ. Health 2006, 79:613-620.
38. Hamel P., Lehmann R., Kube G., Couball B., Leißring B. Modellhafte Sanierung radonbelasteter Wohnungen in Schneeberg 1996, BfS-ST-10/96, Bundesamt für Strahlenschutz.
39. ICRP Publication 65: Protection against Radon-222 at Home and at Work. Annals of the ICRP 1994, vol. 23/2. International Commission on Radiological Protection, Ottawa, CN.
40. Johnson F.R., Luken R.A. Radon risk information and voluntary protection: evidence from a natural experiment. Risk Anal. 1987, 7:97-107.
41. Kennedy C.A., Gray A.M., Denman A.R., Phillips P.S. A cost effectiveness analysis of a residential radon remediation programme in the United Kingdom. Br. J. Cancer 1999, 81:1243-1247.
42. Kennedy C.A., Gray A.M. The cost-effectiveness of radon-induced lung cancer prevention in schools. Int. J. Environ. Health Res. 2000, 10:181-190.
43. Kennedy C.A. Domestic radon remediation rates and reasons for testing. Environ. Manage. Health 2001, 12:459-464.
44. Kennedy C.A., Gray A.M. Cost effectiveness analysis of radon remediation programmes. Sci. Total Environ. 2001, 272:9-15.
45. Konig H.H., Bernert S., Angermeyer M.C. Health Status of the German population: results of a representative survey using the EuroQol questionnaire. Gesundheitswesen 2005, 67:173-182.
46. Konig H.H., Bernert S., Angermeyer M.C., Matschinger H., Martinez M., Vilagut G., Haro J.M., de Girolamo G., de Graaf R., Kovess V., Alonso J. Comparison of population health status in six European countries: results of a representative survey using the EQ-5D questionnaire. Med. Care 2009, 47:255-261.
47. Kotschy-Lang N. Occupation-related lung cancer. Trauma und Berufskrankheit 2001, 3:111-115.
48. Kreienbrock L., Kreuzer M., Gerken M., Dingerkus G., Wellmann J., Keller G., Wichmann H.-E. Case-control study on lung cancer and residential radon in Western Germany. Am. J. Epidemiol. 2001, 153:42-52.
49. Krewski D., Lubin J.H., Zielinski J.M., Alavanja M., Catalan V.S., Field R.W., Klotz J.B., Letourneau E.G., Lynch C.F., Lyon J.I., Sandler D.P., Schoenberg J.B., Steck D.J., Stolwijk J.A., Weinberg C., Wilcox H.B. Residential radon and risk of lung cancer: a combined analysis of 7 North American case-control studies. Epidemiology 2005, 16:137-145.
50. Lee T.R., Macdonald S. Public responses to indoor pollution from radon. Radiat. Prot. Dosimetry 1994, 56:331-337.
51. Letourneau E.G., Krewski D., Zielinski J.M., McGregor R.G. Cost-effectiveness of radon mitigation in Canada. Radiat. Prot. Dosimetry 1992, 45:593-598.
52. Lubin J.H., Boice J.D. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J. Natl. Cancer Inst. 1997, 89:49-57.
53. Menzler S., Schaffrath-Rosario A., Wichmann H.-E., Kreienbrock L. Abschätzung des attributablen Lungenkrebsrisikos in Deutschland durch Radon in Wohnungen 2006, Lech, ecomed MEDIZIN, Landsberg.
54. Nord E. EuroQol: health-related quality of life measurement: valuations of health states by the general public in Norway. Health Policy 1991, 18:25-36.
55. Nord E. Methods for quality adjustment of life years. Soc. Sci. Med. 1992, 34:559-569.
56. NRC The health effects of exposure to indoor radon. BEIR VI Report of the Committee on the Biological Effects of Ionizing Radiation. National Research Council 1999, National Academy Press, Washington, DC.
57. Oberaigner W., Kreienbrock L., Schaffrath Rosario A., Kreuzer M., Wellmann J., Keller G., Gerken M., Langer B., Wichmann H.-E. Radon und Lungenkrebs im Bezirk Imst/Österreich 2002, ecomed Verlagsgesellschaft, Landsberg.
58. Owens D.K. Interpretation of cost-effectiveness analyses. J. Gen. Intern. Med. 1998, 13:716-717.
59. Pearson S., Rawlins M. Quality, innovation, and value for money: NICE and the British National Health Service. J. Am. Med. Assoc. 2005, 294:2618-2622.
60. Philips Z., Bojke L., Sculpher M., Claxton K., Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006, 24:355-371.
61. Pötschke-Langer M., Mons U., Schaller K., Stein S., Kahnert S., Schneider N.K., Nair U., Schunk S., Hersmann H. Tabakatlas Deutschland 2009. D. Krebsforschungszentrum 2009, Steinkopff Verlag, Heidelberg.
62. Riesenfeld E.P., Marcy T.W., Reinier K., Mongeon J.A., Trumbo C.W., Wemple B.E., Kaminsky D.A. Radon awareness and mitigation in Vermont: a public health survey. Health Phys. 2007, 92:425-431.
63. Roserens G.-A., Johner H.-U., Piller G., Imbaumgarten P. Radonhandbuch Schweiz 2000, Bundesamt für Gesundheit Fach- und Informationsstelle Radon, Bern.
64. Ruff L.K., Volmer T., Nowak D., Meyer A. The economic impact of smoking in Germany. Eur. Respir. J. 2000, 16:385-390.
65. Ruosteenoja E., Mäkeläinen I., Rytömaa T., Hakulinen T., Hakama M. Radon and lung cancer in Finland. Health Phys. 1996, 71:185-190.
66. Russell L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. J. Am. Med. Assoc. 1996, 276:1172-1177.
67. Soda H., Oka M., Tomita H., Nagashima S., Soda M., Kohno S. Length and lead time biases in radiologic screening for lung cancer. Respiration 1999, 66:511-517.
68. StBA Statistisches Jahrbuch 2008. StBA 2008, Federal Statstical Office, Wiesbaden.
69. Stigum H., Strand T., Magnus P. Should Radon be reduced in homes? A cost-effect analysis. Health Phys. 2003, 84:227-235.
70. Stinnett A.A., Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med. Decis. Making 1998, 18(Suppl.):68-80.
71. Thomas J., Tomasek L., Fojtikova I., Bernovsky P. Cost-effectiveness of countermeasures against radon in the czech republik: preliminary report. Radiat. Prot. Dosimetry 2008, 1-4. 10.1093/rpd/ncn112.
72. Trippoli S., Vaiani M., Lucioni C., Messori A. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 2001, 19:855-863.
73. VdW Milliardenschwere Belastungen der Wohnungswirtschaft. Magazin des Verbandes der Wohnungs und Immobilienwirtschaft 2004, 11(2004):2.
74. Viscusi W.K. The value of life in legal contexts: survey and critique. Am. Law Econ. Rev. 2000, 2:195-222.
75. Wang Y., Ju C., Stark A.D., Teresi N. Radon awareness, testing, and remediation survey among New York State residents. Health Phys. 2000, 78:641-647.
76. Weinstein N.D., Sandman P.M., Klotz M.L. Public responses to the risk from radon, 1986. Final Report 1987, The State University of New Jersey: Cook College, New Jersey: Rutgers.
77. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. J. Am. Med. Assoc. 1996, 276:1253-1258.
78. Weissflog D., Matthys H., Hasse J., Virchow J.C. Epidemiology and costs of lung cancer in Germany. Pneumologie 2001, 55:333-338.
79. WHO Macroeconomics and Health: Investing in Health for Economic Development 2001, World Health Organization, Commission on Macroeconomics and Health, Genf.
80. WHO WHO Handbook on Indoor Radon: A Public Health Perspective 2009, World Health Organization, Geneva, Switzerland.
81. Wichmann H.-E., Kreienbrock L., Kreuzer M., Gerken M., Dingerkus G., Wellmann J., Keller G. Lungenkrebsrisiko durch Radon in der Bundesrepublik Deutschland (West). Fortschritte in der Umweltmedizin 1998, ecomed, Landsberg. H.-E. Wichmann, H.W. Schlipköter, G. Fülgraff (Eds.).
82. Wichmann H.-E., Gerken M., Wellmann J., Kreuzer M., Kreienbrock L., Keller G., Woelke G., Heinrich J. Lungenkrebsrisiko durch Radon in der Bundesrepublik Deutschland (Ost) - Thüringen und Sachsen 1999, Lech, ecomed, Landsberg.